RxDoctor Payments Data

First Name Unknown Sibghat Tul Llah, MD

Cardiovascular Disease · Little Rock, ARNPI 1356761696

Payments from drug & device makers

$2,235in general payments, 2019–2025

Across 93 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$615
  • Astellas Pharma US Inc$299
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$177
  • Abiomed$144
  • Abbott$136
  • Lexicon Pharmaceuticals, Inc.$120
  • plus $744 from 13 others

What the payments were for

  • Food & beverage$1,80081%
  • Education$43519%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,235 in reported general payments places this provider in the 35th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$124,324
Medicare patients
483
Services billed
1,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban151$116,372
JardianceEmpagliflozin90$93,777
EntrestoSacubitril/Valsartan93$88,938
XareltoRivaroxaban20$22,265
FarxigaDapagliflozin Propanediol26$19,611
Bumetanide62$1,794
Metoprolol Succinate128$1,640
Atorvastatin Calcium125$1,392
Rosuvastatin Calcium84$1,168
Losartan Potassium104$1,034
Spironolactone132$849
Chlorthalidone67$720
Potassium Chloride41$658
Carvedilol76$617
Amiodarone Hcl37$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$74$116,372151 claims
Boehringer IngelheimJardiance$68$93,77790 claims
NovartisEntresto$615$88,93893 claims
Johnson & JohnsonXarelto$65$22,26520 claims
AstraZenecaFarxiga$103$19,61126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →